{
    "nctId": "NCT00344318",
    "title": "To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar\u2122, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age",
    "symPyJSON": {
        "type": "not",
        "operands": [
            {
                "type": "or",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period"
                    },
                    {
                        "type": "variable",
                        "value": "Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose"
                    },
                    {
                        "type": "variable",
                        "value": "Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3"
                    },
                    {
                        "type": "variable",
                        "value": "Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations"
                    },
                    {
                        "type": "variable",
                        "value": "History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b diseases"
                    },
                    {
                        "type": "variable",
                        "value": "History of allergic disease or reactions likely to be exacerbated by any component of the vaccines"
                    },
                    {
                        "type": "variable",
                        "value": "History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease"
                    },
                    {
                        "type": "variable",
                        "value": "Acute disease at the time of enrolment"
                    },
                    {
                        "type": "variable",
                        "value": "Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical"
                    },
                    {
                        "type": "variable",
                        "value": "A family history of congenital or hereditary immunodeficiency"
                    },
                    {
                        "type": "variable",
                        "value": "Major congenital defects or serious chronic illness"
                    },
                    {
                        "type": "variable",
                        "value": "Administration of immunoglobulins and/or any blood products since birth or planned administration during the active phase of the study"
                    }
                ]
            }
        ]
    },
    "symPyExpression": "Not(Or(Symbol('A family history of congenital or hereditary immunodeficiency'), Symbol('Acute disease at the time of enrolment'), Symbol('Administration of immunoglobulins and/or any blood products since birth or planned administration during the active phase of the study'), Symbol('Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical'), Symbol('Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose'), Symbol('History of allergic disease or reactions likely to be exacerbated by any component of the vaccines'), Symbol('History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b diseases'), Symbol('History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease'), Symbol('Major congenital defects or serious chronic illness'), Symbol('Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3'), Symbol('Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations'), Symbol('Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period')))"
}